Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables (2022 - 2026)

Corvus Pharmaceuticals' Receivables history spans 5 years, with the latest figure at $43000.0 for Q1 2026.

  • Quarterly Receivables fell 45.57% to $43000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $43000.0 through Mar 2026, down 45.57% year-over-year, with the annual reading at $37000.0 for FY2025, 50.67% down from the prior year.
  • Receivables came in at $43000.0 for Q1 2026, up from $37000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.2 million in Q4 2022 to a low of $11000.0 in Q3 2023.
  • The 5-year median for Receivables is $61000.0 (2023), against an average of $154416.7.
  • Year-over-year, Receivables crashed 95.58% in 2023 and then soared 1172.73% in 2024.
  • Corvus Pharmaceuticals' Receivables stood at $1.2 million in 2022, then plummeted by 95.58% to $52000.0 in 2023, then soared by 44.23% to $75000.0 in 2024, then plummeted by 50.67% to $37000.0 in 2025, then increased by 16.22% to $43000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Receivables are $43000.0 (Q1 2026), $37000.0 (Q4 2025), and $32000.0 (Q3 2025).